Live Breaking News & Updates on Urological association annual

Stay informed with the latest breaking news from Urological association annual on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Urological association annual and stay connected to the pulse of your community

EMBARK: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

EMBARK: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Naoki-okamura , Astellas-pharma-inc , American-urological-association-annual-meeting , Pfizer-inc , Drug-administration , Prostate-cancerfreedland , Astellas-pharma , New-drug-application , Priority-review , Urological-association-annual

Enfortumab Vedotin/Pembrolizumab Combo, Maintenance Avelumab Continue as Gold Standards in Metastatic Urothelial Cancer

Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research.

United-states , Minnesota , Mayo-clinic-in-rochester , American , Powlest-sridhar , Lancec-pagliaro , Department-of-oncology , American-urological-association-annual-meeting , Division-of-medical-oncology , Urological-association-annual , Medical-oncology

Dr. Barata sobre el Ensayo EMBARK en Pacientes con Cáncer de Próstata no Metastásico de alto Riesgo y Sensible a Hormonas.

Pedro Barata, MD, MSc, discusses the importance of the phase 3 EMBARK trial in patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

United-states , American , Pedro-barata , Gu-medical-oncology-research-program , University-hospitals-seidman-cancer-center , Case-comprehensive-cancer-center , American-urological-association-annual-meeting , Case-western-reserve-university , Oncology-research-program , Urological-association-annual , Prostate-cancer , Onclive-tv

Study Sheds Light on Effect of Type of Treatment on Race-based Differences in Prostate Cancer–Specific Survival

Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.

Massachusetts , United-states , Boston , American , Alexander-putnam-cole , Division-of-urological-surgery , Public-health , American-urological-association-annual-meeting , Harvard-medical-school , Although-black , Urological-association-annual , Hispanic-black

For Smaller Men With Prostate Cancer, Erleada Dose Reduction May Decrease Skin-Related Side Effects

A dose reduction of Erleada may result in fewer skin-related side effects for men with advanced prostate cancer — but only for those with a smaller body size, research showed.

Japan , United-states , Hirosaki , Aomori , American , Japanese , Kyo-togashi , Hirosaki-university-graduate-school-of-medicine , American-urological-association-annual-meeting , Urological-association-annual , Hirosaki-university-graduate-school , Prostate-cancer

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

United-states , American , Apalutamide-erleada , Scott-eggener , University-of-chicago-medicine , American-urological-association-annual-meeting , Urological-association-annual , High-risk , Advanced-prostate-cancer-clinic , Chicago-medicine , Androgen-deprivation-therapy , Adt

89Zr-DFO-girentuximab imaging shows promise in identifying, stratifying renal tumors

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

United-states , American , Brian-shuch , Alvin-carrie-meinhardt , American-urological-association-annual-meeting , Kidney-cancer-research , Kidney-cancer-program , Urological-association-annual , Carrie-meinhardt-endowed-chair , News , Conference , Nct03849118

Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer

Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.

United-states , American , Astellas-pharma , Enzalutamide-xtandi , Stephenj-freedland , Carolina-urologic-research-center , Research-in-cancer , American-urological-association-annual-meeting , Lupron-depot , Urological-association-annual , Neal-shore , Surgical-oncology

Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery

Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

United-states , American , Matthew-milowsky , Nivolumab-opdivo , Lineberger-comprehensive-cancer-center , Urologic-oncology-program , American-urological-association-annual-meeting , Urological-association-annual , Comprehensive-cancer-center , Merican-urological-association-annual-meeting , News , Conference-

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

United-states , American , Ohio-state-university-comprehensive-cancer-center , American-urological-association-annual-meeting , Ohio-state-university-wexner-medical-center , Division-of-urologic-oncology , Bacillus-calmette-gu , Urological-association-annual , Urologic-oncology , Ohio-state-university-comprehensive-cancer , Pembrolizumab-monotherapy